15 years of changing the world - one startup a time: we celebrate all the brave entrepreneurs, the teams, investors, and supporters for the incredible journey together with Venture Kick! Thank you all - you are truly kicking it!!! Read more about our history, shaping the future: https://lnkd.in/eSNkfeuP #SwissStartups #VentureKick
Venture Kick
Wagniskapital- und Private-Equity-Auftraggeber
Schlieren, Zurich 20.357 Follower:innen
1 Million Plus to kick your startup so success. Venture Kick is an initiative of the Kick Foundation.
Info
The Venture Kick philanthropic initiative provides up to CHF 150,000 in seed funding to Swiss startups and offers a well-structured entrepreneurial path toward building a winning business. Startups pitch to expert juries at three stages to obtain funding and gain direct feedback and access to an international network of 200 successful entrepreneurs and investors. Winners of Venture Kick are eligible for a CHF 850,000 investment from the Kickfund and an InnoBooster grant of an additional CHF 150,000. Since its launch in 2007, Venture Kick has supported 1,000 Swiss startup projects with CHF 50.3 million. Thanks to financial support, coaching and networking with investors, this initiative has led to the emergence of 783 thriving startups and the creation of 13,305 jobs. Venture Kick counts a portfolio of 675 active high-tech companies and 68 exits. Venture Kick alumni companies have attracted a total of CHF 7.8 billion and represent 64 companies ranked in the TOP 100 Swiss Startups in 2023. In 2023, Venture Kick paid out 6.3 million Swiss francs to startup projects from Swiss universities to bring science-based innovations to global markets. The Venture Kick Foundation is supported by Gebert Rüf Stiftung, Ernst Göhner Stiftung, Fondation ALCEA, Hauser-Stiftung, André Hoffmann, Hansjörg Wyss, Martin Haefner, Fondation ProTechno, ESA BIC Switzerland, and Swisscom. Apply now: https://www.venturekick.ch/apply
- Website
-
http://www.venturekick.ch
Externer Link zu Venture Kick
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Schlieren, Zurich
- Art
- Nonprofit
- Gegründet
- 2007
- Spezialgebiete
- Startup support and financing, Pre-seed funding, Business training, Startup, Fundraising, Entrepreneurship, venture capital und scaling
Orte
-
Primär
Wiesenstrasse 10A
Schlieren, Zurich 8952, CH
Beschäftigte von Venture Kick
Updates
-
Venture Kick biotech startup sallea raises USD 2.6 million to accelerate 3D Scaffolds for cultivated meat. https://lnkd.in/dNyeq8AA. Congratulations to great team of founders Nicole Kleger (CTO), Simona F. (CEO), and Anna Bünter (COO) With USD 2.6 million in pre-seed funding, led by Founderful and Kost Capital, Sallea plans to accelerate product development and launch pilot projects with cultivators globally. This is the company's first equity investment, adding to USD 1.8 million in non-dilutive grants. Sallea aims to be the leading scaffold provider, driving sustainable animal protein production. About: Sallea's technology enables the manufacturing of such scaffolds addressing the limitations of current systems by providing open, hierarchical porosity and free choice of material for greatly enhanced nutrient transport during the cultivation of meat. Sallea aims at providing these novel scaffolds to foodtech companies enabling the production of whole cut meat. #VentureKick #SwissStartups #Biotech
-
Venture Kick startup Ikerian (former Retinai) secures USD 8 Million in Series B funding to expand RetinAI discovery across Europe! https://lnkd.in/ddzaNM6g. Congratulations to the founders Carlos Ciller (Co-Founder and CEO), Stefanos Apostolopoulos (Co-Founder and CTO) and Sandro De Zanet (Chief Scientific Officer) with their amazing team! The Series B funding was led by strategic investor Sanoptis, with follow-on investments from THINC Ventures (Topcon Healthcare, Inc.), Zürcher Kantonalbank, and Verve Ventures. Sanoptis, operating in over 420 clinics across Europe, is a leading ophthalmology provider network focused on advancing patient care through innovation and modern solutions for eye diseases. About: Ikerian AG develops certified software that accelerates decision-making in clinics and pharma, enhancing efficiency through data-driven insights. Their software organizes and analyzes health data from clinics to global pharma studies. Their first product, RetinAI Discovery, is setting new industry standards by improving clinical study management, enabling real-time data monitoring, and advancing personalized digital precision medicine. #SwissStartups #VentureKick
-
RTDT Laboratories AG receives the CHF 150,000 Kick to optimize wind turbine fleet operation. https://lnkd.in/dEhAXJ4G Congratulations to amazing team of founders: CEO Imad Abdallah, CCO Aris Mukherjee, and CSO Konstantinos Tatsis. About: RTDT is a deep tech company based on research from ETH Zürich that focuses on structural health monitoring and power performance optimization of wind turbines. They combine real-time digital twins of wind turbines with our large proprietary analytical library of physics-based AI models, fully integrated into our SaaS platform to tackle a large number of use cases in a holistic manner. Additionally they have developed Aerosense, a wireless, self-sufficient, best-in-class sensor module for direct data capture on turbine blades, combining aerodynamic, vibrational and acoustic data. #SwissStartups #VentureKick
-
Venture Kick startup Lymphatica Medtech closes EUR 17.9 million funding round to drive Innovation in Lymphedema Treatment. Congratulations to team of founders Marco Pisano (CEO) and Valentina Triacca (CCO) with their great team! https://lnkd.in/g3vxb34i About: Lymphatica, a medical device company, has raised EUR 17.9 million in Series B funding to accelerate the development and validation of LymphoDrain, the first implantable system for treating chronic lymphedema. Lymphedema, a common side effect of cancer therapies, causes limb swelling, pain, and recurrent infections, impacting over 10 million people in Europe and the U.S. This investment will advance Lymphatica's breakthrough technology, which aims to locally replace the lymphatic drainage function, offering unprecedented benefits to patients and healthcare professionals, and improving the lives of millions worldwide. #VentureKick #MedTech #SwissStartups
-
Venture Kick alumni ELDICO Scientific AG secures fresh funding to fuel global expansion! Congrats to founders Gustavo Santiso-Quinones, Gunther Steinfeld and Eric Hovestreydt with their great team! https://lnkd.in/gMEQVxVC Currently, more than 100 customers worldwide rely on ELDICO Scientific, a specialist in electron diffraction technology for crystallography. The company has closed a significant funding round from institutional and private investors to accelerate its global expansion and bolster its commercial operations. About: ELDICO Scientific AG, founded in 2019 at Switzerland Innovation Park Innovaare (PSI), develops innovative electron diffraction instruments for crystallography, enabling nanocrystalline analysis in the sub-micrometer range. The first instrument designed for nano-crystallographic investigations will soon be launched, following a 2018 proof of concept by ETH Zürich and C-CINA Basel under the Swiss Nanoscience Institute's Nano-Argovia project. #VentureKick #SwissStartups
-
LighthouseTech obtains the CHF 150,000 Kick to empower the blind and visually impaired to move safely. https://lnkd.in/d5XpCTit Congrats to the amazing team: COO Nathan Deutsch, CEO Franco Burlando, and CTO Andrea Moroni Stampa! About: Lighthouse Tech has developed smart eyewear combining technology and style to help blind and low-vision people navigate safely. Lighthouse’s eyewear integrates powerful obstacle detection technology in a fashion eyewear frame that complements the white cane by detecting obstacles above ground level. The device alerts users through gentle haptic vibrations, enhancing safety and mobility when used alongside a cane, thereby improving the overall navigation experience. #VentureKick #SwissStartups
-
Venture Kick alumni Voliro secures USD 12 million to transform industrial inspections with drones. https://lnkd.in/dDdfTnr2. Congratulations to founders (Co-Founder and COO Timo Müller with Co-Founder and CTO Marius Fehr) and their great team! The company has successfully secured USD 12 million in a Series A funding round, spearheaded by Cherry Ventures, with additional backing from existing business angels, family offices, and a traditional debt facility. This latest infusion brings the company's total funding to USD 22 million, fueling its efforts to revolutionize industrial inspection, maintenance, and repair work at heights, making these operations safer, more efficient, and cost-effective. About: Voliro provides an advanced flying robot for safer, faster, and more cost-effective Inspection and Maintenance tasks at height. Its tiltable rotor system enables drones to "fly, see, and touch," allowing interaction with surfaces. Equipped with various payloads, like Non-Destructive Testing (NDT) sensors, its 360° design allows inspections from any height and angle. #VentureKick #SwissStartups
-
Meet Helix Robotics' CEO Francesco Stella and CTO-Hardware Kai Junge building a robotic arm platform with cost-effective manufacturing methods and a weight-to-payload ratio. https://lnkd.in/eE-N_a7k The company will focus on developing the first commercial soft manipulator for applications such as collaborative food handling and lab automation. The founders have extensive robotic design and control algorithms expertise, and a European patent protects the proprietary technology. #VentureKick #Robotics #SwissStartups
-
CHF 150'000 for Translation-X to address an unmet medical need in autism spectrum disorder. Congratulations to the excellent team of founders: Peter Scheiffele, Özgür Genç, and Guido Koch. https://lnkd.in/deuE6VRy About: Translation-X is pioneering an innovative therapeutic strategy to address autism spectrum disorders (ASD), focusing on the role of selective mRNA translation in its pathophysiology. Recognizing that impaired mRNA translation is a key factor in a specific subgroup of ASD cases, the company is targeting Map-kinase interacting kinases (MNK) as a potential drug target. By inhibiting MNK activity, Translation-X seeks to normalize mRNA translation and improve neural function, offering a groundbreaking treatment that directly tackles the genetic causes of this form of autism, thus addressing a critical gap in available therapies for core ASD symptoms. #SwissStartups #VentureKick